The enrollment completion is a positive operational milestone, but the stock may have limited near-term catalyst until top-line data in mid-2027. Monitor for any Data Safety Monitoring Board updates or early signals. Traders should weigh the long timeline against the large addressable market.
Price Chart
Executive Summary
Mesoblast announced it has enrolled the target of 300 patients in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. Top-line results are expected in mid-CY2027. The trial has RMAT designation from the FDA, and the company is proceeding with commercial manufacturing in parallel. This milestone de-risks the program but does not provide efficacy data.
Key Facts
- At least 300 patients treated in the placebo-controlled pivotal Phase 3 trial of rexlemestrocel-L for CLBP.
- Top-line results expected in mid-CY2027 after the last patient completes 12-month follow-up.
- Rexlemestrocel-L has FDA RMAT designation, providing eligibility for priority review upon BLA filing.
- Management estimates potential peak year revenue of >$10 billion with single-digit market penetration (forward-looking statement).
- The trial is powered to show significant difference in pain reduction at 12 months vs. sham control.
Financial Impact
No current financial data filed. Management projects potential peak revenue >$10B for this indication, but this is a forward-looking estimate.
Risk Factors
- Trial failure to meet primary endpoint could severely impair the program.
- Regulatory delays or additional data requirements from FDA.
- Competition from other non-opioid pain treatments.
- Dilution risk if Mesoblast needs to raise capital to fund commercial launch.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000066 |
| Exhibit: exhibit991clbppivotaltri.htm | 0001345099-26-000066 |
| Document: 0001345099-26-000066-index-headers.html | 0001345099-26-000066 |
| Document: 0001345099-26-000066-index.html | 0001345099-26-000066 |
| Document: 0001345099-26-000066.txt | 0001345099-26-000066 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | 20-F | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.06 (−22.66%) |
Aug 27, 2026 5w ago | Press Release | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.06 (−22.66%) |
Aug 24, 2026 5w ago | 6-K | $16.64 $15.92 | ▼ −4.33% | ▼ −5.64% | $14.06 (−15.50%) |
Aug 17, 2026 6w ago | Press Release | $17.02 $14.74 | ▼ −13.40% | ▼ −11.42% | $14.06 (−17.39%) |
Jul 30, 2026 9w ago | 6-K | $14.55 $18.18 | ▲ +24.95% | ▲ +20.98% | $14.06 (−3.37%) |
Jul 14, 2026 11w ago | 6-K | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.06 (−16.01%) |
Jul 14, 2026 11w ago | Press Release | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.06 (−16.01%) |
Jul 10, 2026 12w ago | 6-K | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.06 (−8.94%) |
Jul 10, 2026 12w ago | Press Release | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.06 (−8.94%) |
Jul 1, 2026 13w ago | 6-K | $14.09 $14.13 | ▲ +0.28% | ▲ +2.47% | $14.06 (−0.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access